GLAXO ZANAMIVIR IN PHASE III TRIALS FOR INHALED USE IN INFLUENZA; COMPANY WORKING WITH PARTNERS ON FLU TEST: SEREVENT/FLOVENT COMBO FILING PLANNED FOR 1998
Executive Summary
Glaxo Wellcome has begun Phase III trials of the inhaled neuraminidase inhibitor zanamivir for treatment of influenza, acting Head of Internal Medical Affairs Rick Fuller, MD, told a meeting of securities analysts at a company R&D update in New York City May 5.